Revolution Medicines (RVMD) General Counsel reports Form 4 stock sale

Rhea-AI Filing Summary

Revolution Medicines, Inc. reported an insider transaction by its General Counsel, who filed a Form 4 as a single reporting person. On 12/16/2025, the officer sold 2,688 shares of common stock at a price of $76.8169 per share. After this sale, the reporting person beneficially owned 47,884 shares.

The transaction was made pursuant to a pre-arranged Rule 10b5-1 instruction letter adopted on May 31, 2023, to satisfy tax withholding obligations upon vesting of restricted stock units (RSUs) after July 15, 2023. The reported holdings include 147 shares acquired under the company’s Employee Stock Purchase Plan on November 30, 2025, and 38,769 RSUs, which represent additional equity that may be delivered over time as they vest.

Insider Trade Summary

Net Seller: 2,688 shares ($206,484)

Net Sell 1 txn

Insider Cislini Jeff

Role General Counsel

Sold 2,688 shs ($206K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,688	$76.8169	$206K

Holdings After Transaction: Common Stock — 47,884 shares (Direct)

Footnotes (1)

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. Includes 147 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2025. Includes 38,769 restricted stock units.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cislini Jeff

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/16/2025		S(1)		2,688	D	$76.8169	47,884(2)(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

2. Includes 147 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2025.

3. Includes 38,769 restricted stock units.

	/s/ Jack Anders, as Attorney-in-fact for Jeff Cislini	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Revolution Medicines (RVMD) disclose in this Form 4?

The General Counsel of Revolution Medicines, Inc. reported selling 2,688 shares of common stock on 12/16/2025 at $76.8169 per share.

How many Revolution Medicines (RVMD) shares does the reporting person own after the transaction?

Following the reported sale, the General Counsel beneficially owned 47,884 shares of Revolution Medicines common stock.

Was the RVMD insider sale made under a Rule 10b5-1 trading plan?

Yes. The sale was made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023, intended to cover tax withholding on RSU vesting.

What role does the reporting person hold at Revolution Medicines (RVMD)?

The reporting person is an officer of Revolution Medicines, Inc., serving as its General Counsel.

What equity awards and plan shares are included in the RVMD insider’s holdings?

The reported holdings include 147 shares acquired under the Employee Stock Purchase Plan on November 30, 2025 and 38,769 restricted stock units.

Why were Revolution Medicines (RVMD) shares sold in this transaction?

The filing states the transaction was made to satisfy the reporting person’s tax withholding obligations upon vesting of restricted stock units after July 15, 2023.